Special Issue

Phage Therapy and Antimicrobial Innovation

Message from the Guest Editors

The rise of antimicrobial resistance (AMR) has become one of the most pressing global health challenges of the 21st century, rendering many conventional antibiotics ineffective and threatening to reverse decades of medical progress. In this critical context, phage therapy—a century-old concept that utilizes bacteriophages, viruses that specifically target and kill bacteria—has regained significant attention as a potential solution. With the ability to precisely target pathogenic bacteria while sparing beneficial microbiota, phages offer a unique and promising approach to treating multidrug-resistant infections. This Special Issue seeks to explore the resurgence of phage therapy and its role in the broader landscape of antimicrobial innovation. We invite submissions on topics such as the mechanisms of phage action, phage engineering, personalized phage therapy, biofilm disruption, and the clinical applications of phage treatments. We also welcome research that investigates the synergistic potential of phages when combined with antibiotics, immunotherapies, and other novel antimicrobial strategies.

Guest Editors

Prof. Dr. Ronen Hazan
Dr. Lilach Gavish
Dr. Amit Rimon

Deadline for manuscript submissions

31 July 2026

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 10.2
Indexed in PubMed

mdpi.com/si/234350

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 10.2
Indexed in PubMed

mdpi.com/journal/antibiotics

MDPI

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)